| 综述 |
|
|
|
|
| 核医学分子影像探针应用于神经内分泌肿瘤的研究进展 |
颜京( ),张婷婷,赵葵() |
| 浙江大学医学院附属第一医院PET中心，浙江 杭州 310003 |
|
| Application of molecular probes in nuclear imaging of neuroendocrine tumors |
| YAN Jing(),ZHANG Tingting,ZHAO Kui() |
| Department of PET，the First Affiliated Hospital，Zhejiang University School of Medicine，Hangzhou 310003，China |
| 1 |
YAO J C, HASSAN M, PHAN A, et al. One hundred years after “carcinoid”:epidemiology of and prognostic factors for neuroendocrine tumors in 35，825 cases in the United States [J]. J Clin Oncol, 2008, 26(18): 3063-3072.
doi: 10.1200/JCO.2007.15.4377
|
| 2 |
DASARI A, SHEN C, HALPERIN D, et al. Trends in the incidence，prevalence，and survival outcomes in patients with neuroendocrine tumors in the United States [J]. JAMA Oncol, 2017, 3(10): 1335.
doi: 10.1001/jamaoncol.2017.0589
|
| 3 |
KIM J Y, HONG S M, RO J Y . Recent updates on grading and classification of neuroendocrine tumors [J]. Ann Diagnostic Pathol, 2017, 11-16.
doi: 10.1016/j.anndiagpath.2017.04.005
|
| 4 |
王 玲，胡桂兰，乔 真，等. 神经内分泌肿瘤转移灶PET/CT生长抑素受体显像特点分析[J]. 中华核医学与分子影像杂志，2017，37（3）: 132136. DOI: 10.3760/cma.j.issn.2095-2848.2017.03.003 .
|
| 5 |
PRASAD V, AMBROSINI V, HOMMANN M, et al. Detection of unknown primary neuroendocrine tumours （CUP-NET） using 68Ga-DOTA-NOC receptor PET/CT [J]. Eur J Nucl Med Mol Imag, 2010, 37(1): 67-77.
doi: 10.1007/s00259-009-1205-y
|
| 6 |
姚晓晨，王 峰. 胃肠胰神经内分泌肿瘤的影像学诊断[J]. 浙江大学学报（医学版），2016，45（1）: 51–55. DOI: 10.3785/j.issn.1008-9292.2016.01.08 .
|
| 7 |
HAS SIMSEK D, KUYUMCU S, TURKMEN C, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastro- enteropancreatic neuroendocrine tumors? [J]. J Nucl Med, 2014, 55(11): 1811-1817.
doi: 10.2967/jnumed.114.142224
|
| 8 |
BUCAU M, LAURENT-BELLUE A, POTé N, et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation [J]. Neuroendocrinology, 2018, 106(3): 274-282.
doi: 10.1159/000480239
|
| 9 |
VAN ESSEN M, SUNDIN A, KRENNING E P, et al. Neuroendocrine tumours:the role of imaging for diagnosis and therapy [J]. Nat Rev Endocrinol, 2014, 10(2): 102-114.
doi: 10.1038/nrendo.2013.246
|
| 10 |
ZER A, DOMACHEVSKY L, RAPSON Y, et al. The role of 18F-FDG PET/CT on staging and prognosis in patients with small cell lung cancer [J]. Eur Radiol, 2016, 26(9): 3155-3161.
doi: 10.1007/s00330-015-4132-2
|
| 11 |
KAUHANEN S, SCHALIN-J?NTTI C, SEPP?NEN M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer [J]. J Nucl Med, 2011, 52(12): 1855-1863.
doi: 10.2967/jnumed.111.094771
|
| 12 |
GEIJER H, BREIMER L H . Somatostatin receptor PET/CT in neuroendocrine tumours:update on systematic review and meta-analysis [J]. Eur J Nucl Med Mol Imag, 2013, 40(11): 1770-1780.
doi: 10.1007/s00259-013-2482-z
|
| 13 |
KAEMMERER D, PETER L, LUPP A, et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours [J]. Eur J Nucl Med Mol Imag, 2011, 38(9): 1659-1668.
doi: 10.1007/s00259-011-1846-5
|
| 14 |
LOCOCO F, PEROTTI G, CARDILLO G, et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid [J/OL]. Clin Nucl Med, 2015, 40(3): e183-e189.
doi: 10.1097/RLU.0000000000000641
|
| 15 |
NASWA N, SHARMA P, SUMAN KC S, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma [J]. Nucl Med Commun, 2012, 33(7): 766-774.
doi: 10.1097/MNM.0b013e3283541157
|
| 16 |
HERRMANN K, CZERNIN J, WOLIN E M, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors:the referring physician’s perspective [J]. J Nucl Med, 2015, 56(1): 70-75.
doi: 10.2967/jnumed.114.148247
|
| 17 |
LONG T, YANG N, ZHOU M, et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms [J]. Clin Nucl Med, 2019, 44(6): 452-458.
doi: 10.1097/RLU.0000000000002578
|
| 18 |
刘会攀，陈 跃. 放射性核素诊治神经内分泌肿瘤的应用进展[J]. 中华核医学与分子影像杂志，2019，39（9）: 564567.DOI: 10.3760/cma.j.issn.2095-2848.2019.09.015 .
|
| 19 |
GRISANTI S, FILICE A, BASILE V, et al. Treatment with 90Y/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors [J/OL]. J Clin Endocrinol Metab, 2020, 105(3): e1-e5.
doi: 10.1210/clinem/dgz091
|
| 20 |
RUFINI V, BAUM R P, CASTALDI P, et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors [J]. Abdom Imag, 2012, 37(6): 1004-1020.
doi: 10.1007/s00261-012-9871-9
|
| 21 |
SANTHANAM P, CHANDRAMAHANTI S, KROISS A, et al. Nuclear imaging of neuroendocrine tumors with unknown primary:why，when and how? [J]. Eur J Nucl Med Mol Imag, 2015, 42(7): 1144-1155.
doi: 10.1007/s00259-015-3027-4
|
| 22 |
NANNI C, RUBELLO D, FANTI S . 18F-DOPA PET/CT and neuroendocrine tumours[J]. Eur J Nucl Med Mol Imag, 2006, 33(5): 509-513.
doi: 10.1007/s00259-006-0079-5
|
| 23 |
BANDOPADHYAYA G P，KUMAR A，KUMARI J. Role of （18）F-DOPA PET/CT and （131）I-MIBG planar scintigraphy in evaluating patients with pheochromocytoma[J]. Hell J Nucl Med，2015，18 Suppl 1:141 .
|
| 24 |
BACCA A, CHIACCHIO S, ZAMPA V, et al. Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas [J]. Clin Nucl Med, 2014, 39(1): 14-20.
doi: 10.1097/RLU.0000000000000242
|
| 25 |
BOZKURT M F, VIRGOLINI I, BALOGOVA S, et al. Erratum to:Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA [J]. Eur J Nucl Med Mol Imag, 2017, 44(12): 2150-2151.
doi: 10.1007/s00259-017-3807-0
|
| 26 |
IMPERIALE A, RUST E, GABRIEL S, et al. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin:relation to tumor origin and differentiation[J]. J Nucl Med, 2014, 55(3): 367-372.
doi: 10.2967/jnumed.113.126896
|
| 27 |
KUIK W J, KEMA I P, BROUWERS A H, et al. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3，4-dihydroxy-L-phenylalanine （18F-DOPA），produced by a new nucleophilic substitution approach，compared with carrier-added 18F-DOPA，prepared by conventional electrophilic substitution [J] . J Nucl Med, 2015, 56(1): 106-112.
doi: 10.2967/jnumed.114.145730
|
| 28 |
ORLEFORS H, SUNDIN A, LU L, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography [J]. Eur J Nucl Med Mol Imag, 2006, 33(1): 60-65.
doi: 10.1007/s00259-005-1891-z
|
| 29 |
PASHANKAR F D，O′DORISIO M S，MENDA Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use[J]. J Nucl Med，2005，46 Suppl 1:55S–61S .
|
| 30 |
YAMAMOTO S, HELLMAN P, WASSBERG C, et al. 11C-hydroxyephedrine positron emission tomography imaging of pheochromocytoma:a single center experience over 11 years [J]. J Clin Endocrinol Metab, 2012, 97(7): 2423-2432.
doi: 10.1210/jc.2011-3342
|
| 31 |
HAHNER S, SUNDIN A . Metomidate-based imaging of adrenal masses [J]. HORM CANC, 2011, 2(6): 348-353.
doi: 10.1007/s12672-011-0093-3
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
